Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H27NO4 |
Molecular Weight | 345.4334 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cc1cccc(c1)OCC(CNCCc2ccc(c(c2)OC)OC)O
InChI
InChIKey=HXLAFSUPPDYFEO-UHFFFAOYSA-N
InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
Molecular Formula | C20H27NO4 |
Molecular Weight | 345.4334 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.drugbank.ca/drugs/DB01295Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26961574 | https://www.ncbi.nlm.nih.gov/pubmed/18426954 | https://www.ncbi.nlm.nih.gov/pubmed/7620695 | https://www.ncbi.nlm.nih.gov/pubmed/2572566
Sources: https://www.drugbank.ca/drugs/DB01295
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26961574 | https://www.ncbi.nlm.nih.gov/pubmed/18426954 | https://www.ncbi.nlm.nih.gov/pubmed/7620695 | https://www.ncbi.nlm.nih.gov/pubmed/2572566
Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker. Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure. Bevantolol was discovered and developed by Warner-Lambert but in January 1989 the company announced that it had withdrawn the New Drug Application. As of 2016 it wasn't marketed in the US, UK, or Europe.
CNS Activity
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacology of bevantolol hydrochloride. | 1986 Nov 26 |
|
Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. | 1987 Jul |
|
Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. | 2007 Jul 12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2572566
The patients were given bevantolol 100 mg twice daily for four weeks. Exercise tolerance testing was performed at the end of this period; ten to twelve hours after the last dose. If the patient’s symptoms were controlled during this period, as shown by at least 30% increased exercise time, the double-blind phase was conducted on the same daily dose. Patients who were not controlled received bevantolol 400 mg daily either once in the morning or 200 mg twice daily during the double-blind randomised cross-over phase.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6311582
Effects of Bevantolol on salbutamol (3 × 10^-7 M)-induded increases in impulse-evoked 3H efflux from spirally cut pulmonary arteries of guinea-pigs was evaluated. Strips were incubated for 60 min in 10^-7 M [3H]norepinephrine, rinsed, set up then superfused with Krebs solution. Transmural field stimulation (5 Hz, 2 msec, 10V, 20 sec) was applied twice, 90 min and 120 min after the start of superfusion, Bevantolol were superfused simultaneously with salbutamol between 2 periods of stimulation. In the abscissa, the total 3H efflux caused by the 2rid stimulation is expressed as a percentage of that caused by the 1st stimulation.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 22:07:22 UTC 2021
by
admin
on
Fri Jun 25 22:07:22 UTC 2021
|
Record UNII |
34ZXW6ZV21
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C07AB06
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
||
|
NCI_THESAURUS |
C29576
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
||
|
WHO-VATC |
QC07BB06
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
||
|
WHO-ATC |
C07BB06
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
||
|
WHO-VATC |
QC07AB06
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL314010
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
2372
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
DB01295
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
C021148
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
SUB05808MIG
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
C79556
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
59170-23-9
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
360
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
BEVANTOLOL
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
4115
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
34ZXW6ZV21
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | |||
|
M2465
Created by
admin on Fri Jun 25 22:07:22 UTC 2021 , Edited by admin on Fri Jun 25 22:07:22 UTC 2021
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |